CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
0.7200
-0.0100 (-1.37%)
At close: Apr 1, 2025, 4:00 PM
0.7223
+0.0023 (0.32%)
After-hours: Apr 1, 2025, 4:40 PM EDT
Company Description
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies.
The company was incorporated in 2021 and is based in South San Francisco, California.
CERo Therapeutics Holdings, Inc.
Country | United States |
Founded | 2017 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 9 |
CEO | Christopher Ehrlich |
Contact Details
Address: 201 Haskins Way, Suite 230 South San Francisco, California 94080 United States | |
Phone | 215 731 9450 |
Website | cero.bio |
Stock Details
Ticker Symbol | CERO |
Exchange | NASDAQ |
Stock Type | Common Stock |
Share Class | Class A Shares |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001870404 |
ISIN Number | US71902K1051 |
Employer ID | 87-1088814 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Christopher B. Ehrlich M.B.A. | Chief Executive Officer and Chair |
Dr. Lawrence Corey M.D. | Co-founder and Head of Scientific Advisory Board |
Andrew Albert Kucharchuk M.B.A. | Chief Financial Officer |
Dr. Kristen Pierce Ph.D. | Chief Development Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 1, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
Feb 13, 2025 | 424B3 | Prospectus |
Feb 13, 2025 | 424B3 | Prospectus |
Feb 13, 2025 | 424B3 | Prospectus |
Feb 13, 2025 | 424B3 | Prospectus |
Feb 12, 2025 | 8-K | Current Report |
Feb 7, 2025 | SCHEDULE 13D/A | Filing |
Feb 7, 2025 | 424B3 | Prospectus |
Feb 6, 2025 | 8-K | Current Report |
Feb 5, 2025 | EFFECT | Notice of Effectiveness |